65,437 trials
Epilepsy · Seizures
Primary: Number of Participants With Severe Adverse Events (Increase in Seizure Frequency by More Than 100% Leading to Emergency Room Visit or Hospitalization). — 0 Participants
Pleural Malignant Mesothelioma
Primary: 3-month Progression Free Survival Rate — 3 Participants
Mental Disorders
Primary: Internalized Stigma of Mental Illness Scale, Change in Internalized Stigma — 2.18; 2.09; 2.11; 2.05 Score on a scale. — p=0.66
Languages
Primary: RTs for Picture Naming With the Factors Language (L1, L2) and Block (Switching, Non-Switching) — 1103.32; 1107.26; 1098.82; 1158.91 Milliseconds — p=0.932
Breast Cancer
Primary: Number of Participants for Which DBT Altered Surgical Plan — 0 Participants
Acute Bacterial Skin and Skin Structure Infections
Primary: Hospital Admission Rate at Initial Episode of Care — 60; 27; 96; 126 Participants — p=<0.001
Glioblastoma
Primary: Number of Patients With Adverse Events — 35 Participants
Squamous Cell Carcinoma of the Head and Neck · Nasopharyngeal Carcinoma · Salivary Gland Cancer
Primary: Local Control Rate — 1; 5 Participants
Breast Neoplasm
Primary: Negative Predictive Value — 88.2; 85.7; 87.1 percentage of participants
Melanoma
Primary: Summary of Best Overall Response Following Twice Daily Administration of PL3397 at 1000 mg/Day In Participants With Unresectable or Advanced KIT-mutated Melanoma — 0; 1…
Diabetes · Diabetes Mellitus, Type 2 · Cholesterolemia
Primary: Percent Change From Baseline to Week 12/End of Study (EOS) in Low-density Lipoprotein Cholesterol (LDL-C) — -38.8; -19.2; 0.9 Percent change — p=<0.001
Osteoarthritis · Post-traumatic Arthritis
Primary: Difference in Absolute Mechanical Axis Alignment Angle Between Subjects Operated on With RUI and SUI TKA Instrumentation — 2.55; 2.97 Degrees — p=0.028
BRCA1 Mutation · BRCA2 Mutation · Atypia Suspicious for Malignancy
Primary: Concordance Between Cytological Findings From Fallopian Tubes to Surgical Histology Results. — 42; 2 fallopian tubes
Influenza · Influenza Vaccines
Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease — 5.6; 5.5; 5.6; 5.4 Titers
Asthma · Mastocytosis · Mast Cell Activation Syndrome
Primary: Mast Cell Activation Test Results for Validation Group — 6; 2; 0; 4 Participants